Gastroenterology continues to evolve with advancements in AI, digital health, endoscopic procedures, and quality improvement initiatives. These five physicians are driving change and shaping the future of the specialty:
Author: Abhay Panchal
BMS presented data from the CheckMate-8HW trial, demonstrating that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves outcomes for patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) mCRC. The dual therapy:
Disorders of gut–brain interaction (DGBI) often overlap with non-gastrointestinal conditions such as fibromyalgia, headaches, gynecological and urological disorders, sleep disturbances, and chronic fatigue. This complex interplay of symptoms not only complicates diagnosis but also alters treatment approaches and impacts patient outcomes. Recent research from the Rome Foundation Working Team highlights shared pathophysiology between these conditions, although the mechanisms remain unclear.
In this episode of the UEG Talks conversation between Maria Vehreschild and Pradeep Mundre, we delve into the complexities of the faecal microbiome and the role of faecal microbiota transplantation (FMT) in treating various diseases, particularly C. difficile infections and inflammatory bowel disease (IBD). The discussion covers the historical context of FMT, its mechanisms of action, current treatment guidelines, safety considerations, and the various delivery methods. The conversation also emphasises the need for further research and the importance of professional standards in FMT practices.
A little-known Chinese AI startup, DeepSeek, sent shockwaves through the tech world by releasing an OpenAI-like assistant that quickly climbed to the No. 1 spot on Apple’s App Store. The model, DeepSeek R1, reportedly rivals and even surpasses OpenAI’s cutting-edge AI while operating at a fraction of the cost. The revelation caused U.S. tech stocks to tumble, raising urgent policy questions in Washington. Despite bipartisan efforts to curb China’s AI progress through export controls and tech restrictions, DeepSeek’s achievement suggests that these policies may not be working as intended. The development has sparked two contrasting reactions in the U.S.: Some…
A new investigational blood test for colorectal cancer (CRC) demonstrated encouraging results in the PREEMPT CRC study, the largest trial of any blood-based CRC screening test to date. Presented at ASCO GI 2025, the study reported 79.2% sensitivity and 91.5% specificity for CRC detection among 27,010 average-risk adults. While the test met primary endpoints, its sensitivity for advanced precancerous lesions was only 12.5%, indicating the need for further optimization.
Albany Gastroenterology Associates (Albany Gastro) has reported a data breach to the Vermont Attorney General, revealing that an unauthorized party accessed sensitive patient information, including names and Social Security numbers. The breach, detected on November 19, 2024, compromised files as early as November 10, 2024. Following an internal investigation with cybersecurity experts, Albany Gastro began notifying affected individuals on January 28, 2025.
In this week’s Impact Factor, Dr. F. Perry Wilson delves into the latest study on GLP-1 receptor agonists—drugs like Ozempic and Mounjaro—published in Nature Medicine. Initially developed for diabetes, these drugs have shown remarkable benefits beyond blood sugar control, including significant weight loss and reductions in smoking, alcohol use, and even compulsive behaviors. While concerns remain about long-term effects and applicability to broader populations, the study suggests that these drugs may be the ultimate “anticonsumption” therapy—addressing some of the most pressing health challenges of modern society. Could we be looking at the most transformative drug class of our era?
Artificial intelligence (AI) is rapidly shaping the landscape of gastroenterology and endoscopy, offering new opportunities to improve diagnostics, treatment, and workflow efficiency. Despite numerous AI applications being explored in academic research, regulatory authorization remains a bottleneck, limiting real-world adoption. This paper explores the role of industry in fostering AI integration by addressing ethical considerations, regulatory pathways, data security, and commercialization strategies.
Gastroenterology experts recently joined Becker’s to highlight the most promising areas for Ambulatory Surgery Center (ASC) growth in the coming years. With increasing demand for cost-effective, high-quality GI care, ASCs are well-positioned to expand their role in the healthcare landscape. Here are three key areas they identified: